{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,2]],"date-time":"2026-03-02T06:57:01Z","timestamp":1772434621534,"version":"3.50.1"},"reference-count":106,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,3,2]],"date-time":"2026-03-02T00:00:00Z","timestamp":1772409600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100015498","name":"Innov\u00e1ci\u00f3s \u00e9s Technol\u00f3giai Miniszt\u00e9rium","doi-asserted-by":"publisher","award":["K139059"],"award-info":[{"award-number":["K139059"]}],"id":[{"id":"10.13039\/501100015498","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["por-journal.com"],"crossmark-restriction":true},"short-container-title":["Pathol. Oncol. Res."],"abstract":"<jats:p>Immune checkpoint inhibitor (ICI) therapy has become a firmly integrated component of the systemic treatment repertoire for locally advanced and metastatic urothelial bladder cancer (UBC). Over the past decade, multiple ICIs have demonstrated meaningful clinical activity, and their indications have expanded across treatment lines, including second-line therapy after platinum, first-line therapy for cisplatin-ineligible disease, avelumab maintenance following chemotherapy, and, more recently, combination strategies such as pembrolizumab plus enfortumab vedotin. Despite these advances, patient responses to ICIs remain highly heterogeneous. While a subset of patients achieves substantial tumor regression and long-term survival, a considerable proportion derives little or no benefit. The rapidly evolving therapeutic landscape - encompassing antibody-drug conjugates, targeted agents, and perioperative ICI approvals - further emphasizes the need to identify which patients are most likely to respond to immunotherapy. Given the marked variability in therapeutic sensitivity and the increasing availability of alternative effective treatments, accurate prediction of ICI efficacy is becoming increasingly crucial for personalized treatment selection. In this review, we provide a comprehensive overview of currently established and emerging biomarkers of ICI response in UBC, including PD-L1 immunohistochemistry, serum inflammatory markers, tumor mutational burden, histology and molecular subtypes, gene expression patterns and microbiome features. We discuss their strengths, limitations, and potential translational relevance, highlighting ongoing challenges and future directions.<\/jats:p>","DOI":"10.3389\/pore.2026.1612333","type":"journal-article","created":{"date-parts":[[2026,3,2]],"date-time":"2026-03-02T06:10:19Z","timestamp":1772431819000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Prognostic and predictive factors of immune checkpoint inhibitor therapy in urinary bladder cancer"],"prefix":"10.3389","volume":"32","author":[{"given":"Melinda","family":"V\u00e1radi","sequence":"first","affiliation":[{"name":"Department of Urology, Semmelweis University","place":["Budapest, Hungary"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bal\u00e1zs","family":"Magyar","sequence":"additional","affiliation":[{"name":"Department of Urology, Semmelweis University","place":["Budapest, Hungary"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"\u00c1d\u00e1m","family":"Sz\u00e9les","sequence":"additional","affiliation":[{"name":"Department of Urology, Semmelweis University","place":["Budapest, Hungary"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S\u00e1ra","family":"Korda","sequence":"additional","affiliation":[{"name":"Department of Urology, Semmelweis University","place":["Budapest, Hungary"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bernadett","family":"N\u00e9meth","sequence":"additional","affiliation":[{"name":"Department of Urology, Semmelweis University","place":["Budapest, Hungary"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Barbara","family":"Simon","sequence":"additional","affiliation":[{"name":"Department of Urology, Semmelweis University","place":["Budapest, Hungary"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Henning","family":"Reis","sequence":"additional","affiliation":[{"name":"Institute of Pathology, University Medicine Essen, University of Duisburg-Essen","place":["Essen, Germany"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Csilla","family":"Ol\u00e1h","sequence":"additional","affiliation":[{"name":"Department of Urology, University of Duisburg-Essen","place":["Essen, Germany"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Orsolya","family":"Horv\u00e1th","sequence":"additional","affiliation":[{"name":"Department of Genitourinary Medical Oncology and Pharmacology, National Institute of Oncology","place":["Budapest, Hungary"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B\u00e1lint","family":"D\u00e9r","sequence":"additional","affiliation":[{"name":"Department of Urology, Semmelweis University","place":["Budapest, Hungary"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P\u00e9ter","family":"Nyir\u00e1dy","sequence":"additional","affiliation":[{"name":"Department of Urology, Semmelweis University","place":["Budapest, Hungary"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tibor","family":"Szarvas","sequence":"additional","affiliation":[{"name":"Department of Urology, Semmelweis University","place":["Budapest, Hungary"]},{"name":"Department of Urology, University of Duisburg-Essen","place":["Essen, Germany"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,3,2]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"970","DOI":"10.1093\/annonc\/mdz127","article-title":"Randomized phase III KEYNOTE-045 trial of pembrolizumab versus paclitaxel, docetaxel, or vinflunine in recurrent advanced urothelial cancer: results of >2 years of follow-up","volume":"30","author":"Fradet","year":"2019","journal-title":"Ann Oncol"},{"key":"B2","doi-asserted-by":"publisher","first-page":"1909","DOI":"10.1016\/S0140-6736(16)00561-4","article-title":"Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial","volume":"387","author":"Rosenberg","year":"2016","journal-title":"Lancet"},{"key":"B3","doi-asserted-by":"publisher","first-page":"1218","DOI":"10.1056\/NEJMoa2002788","article-title":"Avelumab maintenance therapy for advanced or metastatic urothelial carcinoma","volume":"383","author":"Powles","year":"2020","journal-title":"N Engl J Med"},{"key":"B4","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1056\/NEJMoa2312117","article-title":"Enfortumab vedotin and pembrolizumab in untreated advanced urothelial cancer","volume":"390","author":"Powles","year":"2024","journal-title":"N Engl J Med"},{"key":"B5","doi-asserted-by":"publisher","first-page":"2102","DOI":"10.1056\/NEJMoa2034442","article-title":"Adjuvant nivolumab versus placebo in muscle-invasive urothelial carcinoma","volume":"384","author":"Bajorin","year":"2021","journal-title":"N Engl J Med"},{"key":"B6","doi-asserted-by":"publisher","first-page":"1773","DOI":"10.1056\/NEJMoa2408154","article-title":"Perioperative durvalumab with neoadjuvant chemotherapy in operable bladder cancer","volume":"391","author":"Powles","year":"2024","journal-title":"N Engl J Med"},{"key":"B7","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1007\/s00262-025-04224-8","article-title":"Combining molecular patterns and clinical data for better immune checkpoint inhibitor prediction in metastatic urothelial carcinoma","volume":"74","author":"Varadi","year":"2025","journal-title":"Cancer Immunol Immunother"},{"key":"B8","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1016\/S1470-2045(17)30065-7","article-title":"Nivolumab in metastatic urothelial carcinoma after platinum therapy (checkMate 275): a multicentre, single-arm, phase 2 trial","volume":"18","author":"Sharma","year":"2017","journal-title":"Lancet Oncol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1056\/NEJMoa1613683","article-title":"Pembrolizumab as second-line therapy for advanced urothelial carcinoma","volume":"376","author":"Bellmunt","year":"2017","journal-title":"N Engl J Med"},{"key":"B10","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1016\/j.eururo.2025.02.019","article-title":"European association of urology guidelines on muscle-invasive and metastatic bladder cancer: summary of the 2025 guidelines","volume":"87","author":"van der Heijden","year":"2025","journal-title":"Eur Urol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"152267","DOI":"10.1016\/j.anndiagpath.2024.152267","article-title":"PD-L1 immunohistochemical expression in bladder urothelial cancer with SP263, SP142 and 22C3 antibodies: a comparative study","volume":"69","author":"Paliogiannis","year":"2024","journal-title":"Ann Diagn Pathol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1158\/2326-6066.CIR-24-0649","article-title":"Different PD-L1 assays reveal distinct immunobiology and clinical outcomes in urothelial cancer","volume":"13","author":"Galsky","year":"2025","journal-title":"Cancer Immunol Res"},{"key":"B13","doi-asserted-by":"publisher","first-page":"110693","DOI":"10.18632\/oncotarget.22690","article-title":"Regulation of PD-1\/PD-L1 pathway and resistance to PD-1\/PD-L1 blockade","volume":"8","author":"Bai","year":"2017","journal-title":"Oncotarget"},{"key":"B14","doi-asserted-by":"publisher","first-page":"4639","DOI":"10.1038\/s41388-018-0303-3","article-title":"Genetic, transcriptional and post-translational regulation of the programmed death protein ligand 1 in cancer: biology and clinical correlations","volume":"37","author":"Zerdes","year":"2018","journal-title":"Oncogene"},{"key":"B15","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1016\/S0140-6736(20)30230-0","article-title":"Atezolizumab with or without chemotherapy in metastatic urothelial cancer (IMvigor130): a multicentre, randomised, placebo-controlled phase 3 trial","volume":"395","author":"Galsky","year":"2020","journal-title":"Lancet"},{"key":"B16","doi-asserted-by":"publisher","first-page":"1574","DOI":"10.1016\/S1470-2045(20)30541-6","article-title":"Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial","volume":"21","author":"Powles","year":"2020","journal-title":"Lancet Oncol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1126\/science.aan6733","article-title":"Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade","volume":"357","author":"Le","year":"2017","journal-title":"Science"},{"key":"B18","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1126\/science.aaa1348","article-title":"Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer","volume":"348","author":"Rizvi","year":"2015","journal-title":"Science"},{"key":"B19","doi-asserted-by":"publisher","first-page":"e2311181","DOI":"10.1001\/jamanetworkopen.2023.11181","article-title":"Assessment of tumor mutational burden and outcomes in patients with diverse advanced cancers treated with immunotherapy","volume":"6","author":"Aggarwal","year":"2023","journal-title":"JAMA Netw Open"},{"key":"B20","doi-asserted-by":"publisher","first-page":"4685","DOI":"10.1158\/1078-0432.CCR-21-0327","article-title":"FDA approval summary: pembrolizumab for the treatment of tumor mutational burden-high solid tumors","volume":"27","author":"Marcus","year":"2021","journal-title":"Clin Cancer Res"},{"key":"B21","doi-asserted-by":"publisher","first-page":"3753","DOI":"10.1158\/1078-0432.CCR-18-4070","article-title":"FDA approval summary: pembrolizumab for the treatment of microsatellite instability-high solid tumors","volume":"25","author":"Marcus","year":"2019","journal-title":"Clin Cancer Res"},{"key":"B22","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1186\/s13073-017-0424-2","article-title":"Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden","volume":"9","author":"Chalmers","year":"2017","journal-title":"Genome Med"},{"key":"B23","doi-asserted-by":"publisher","first-page":"2189","DOI":"10.1056\/NEJMoa1406498","article-title":"Genetic basis for clinical response to CTLA-4 blockade in melanoma","volume":"371","author":"Snyder","year":"2014","journal-title":"N Engl J Med"},{"key":"B24","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1016\/j.annonc.2024.03.007","article-title":"Tumor mutational burden for the prediction of PD-(L)1 blockade efficacy in cancer: challenges and opportunities","volume":"35","author":"Wang","year":"2024","journal-title":"Ann Oncol"},{"key":"B25","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1186\/s13046-018-0702-x","article-title":"Tearing down the walls: FDA approves next generation sequencing (NGS) assays for actionable cancer genomic aberrations","volume":"37","author":"Allegretti","year":"2018","journal-title":"J Exp Clin Cancer Res"},{"key":"B26","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1093\/annonc\/mdy495","article-title":"Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic","volume":"30","author":"Chan","year":"2019","journal-title":"Ann Oncol"},{"key":"B27","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1016\/j.ccell.2020.10.001","article-title":"The challenges of tumor mutational burden as an immunotherapy biomarker","volume":"39","author":"Jardim","year":"2021","journal-title":"Cancer Cell"},{"key":"B28","doi-asserted-by":"publisher","first-page":"2303","DOI":"10.1002\/ijc.32002","article-title":"Measurement of tumor mutational burden (TMB) in routine molecular diagnostics: in silico and real-life analysis of three larger gene panels","volume":"144","author":"Endris","year":"2019","journal-title":"Int J Cancer"},{"key":"B29","doi-asserted-by":"publisher","first-page":"882","DOI":"10.1016\/j.jmoldx.2021.04.008","article-title":"Validation of a targeted next-generation sequencing panel for tumor mutation burden analysis: results from the onconetwork immuno-oncology consortium","volume":"23","author":"Fenizia","year":"2021","journal-title":"J Mol Diagn"},{"key":"B30","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1007\/s00428-021-03093-7","article-title":"Tumor mutation burden testing: a survey of the international quality network for pathology (IQN path)","volume":"479","author":"Fenizia","year":"2021","journal-title":"Virchows Arch"},{"key":"B31","doi-asserted-by":"publisher","first-page":"5120","DOI":"10.1158\/1078-0432.CCR-19-4162","article-title":"Nivolumab in patients with advanced platinum-resistant urothelial carcinoma: efficacy, safety, and biomarker analyses with extended Follow-up from CheckMate 275","volume":"26","author":"Galsky","year":"2020","journal-title":"Clin Cancer Res"},{"key":"B32","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/S0140-6736(16)32455-2","article-title":"Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial","volume":"389","author":"Balar","year":"2017","journal-title":"Lancet"},{"key":"B33","doi-asserted-by":"publisher","first-page":"5353","DOI":"10.1158\/1078-0432.CCR-23-3518","article-title":"Association of tumor mutational burden and PD-L1 with the efficacy of pembrolizumab with or without chemotherapy versus chemotherapy in advanced urothelial carcinoma","volume":"30","author":"Flechon","year":"2024","journal-title":"Clin Cancer Res"},{"key":"B34","doi-asserted-by":"publisher","first-page":"e7411","DOI":"10.1002\/cam4.7411","article-title":"Avelumab first-line maintenance in advanced urothelial carcinoma: complete screening for prognostic and predictive factors using machine learning in the JAVELIN bladder 100 phase 3 trial","volume":"13","author":"Manitz","year":"2024","journal-title":"Cancer Med"},{"key":"B35","doi-asserted-by":"publisher","first-page":"3353","DOI":"10.1200\/JCO.18.01148","article-title":"Pembrolizumab as neoadjuvant therapy before radical cystectomy in patients with muscle-invasive urothelial bladder carcinoma (PURE-01): an open-label, single-arm, phase II study","volume":"36","author":"Necchi","year":"2018","journal-title":"J Clin Oncol"},{"key":"B36","doi-asserted-by":"publisher","first-page":"1706","DOI":"10.1038\/s41591-019-0628-7","article-title":"Clinical efficacy and biomarker analysis of neoadjuvant atezolizumab in operable urothelial carcinoma in the ABACUS trial","volume":"25","author":"Powles","year":"2019","journal-title":"Nat Med"},{"key":"B37","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1016\/j.eururo.2019.09.006","article-title":"A consensus molecular classification of muscle-invasive bladder cancer","volume":"77","author":"Kamoun","year":"2020","journal-title":"Eur Urol"},{"key":"B38","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.3390\/ijms23031133","article-title":"Novel therapeutic opportunities in neoadjuvant setting in urothelial cancers: a new horizon opened by molecular classification and immune checkpoint inhibitors","volume":"23","author":"Iacovino","year":"2022","journal-title":"Int J Mol Sci"},{"key":"B39","doi-asserted-by":"publisher","first-page":"2126","DOI":"10.1038\/s41467-023-37568-9","article-title":"Expression-based subtypes define pathologic response to neoadjuvant immune-checkpoint inhibitors in muscle-invasive bladder cancer","volume":"14","author":"Robertson","year":"2023","journal-title":"Nat Commun"},{"key":"B40","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1016\/j.eururo.2019.02.017","article-title":"The cancer genome atlas expression subtypes stratify response to checkpoint inhibition in advanced urothelial cancer and identify a subset of patients with high survival probability","volume":"75","author":"Kim","year":"2019","journal-title":"Eur Urol"},{"key":"B41","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1038\/nature25501","article-title":"TGFbeta attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells","volume":"554","author":"Mariathasan","year":"2018","journal-title":"Nature"},{"key":"B42","doi-asserted-by":"publisher","first-page":"2098","DOI":"10.1016\/j.ccell.2024.10.016","article-title":"Molecular heterogeneity in urothelial carcinoma and determinants of clinical benefit to PD-L1 blockade","volume":"42","author":"Hamidi","year":"2024","journal-title":"Cancer Cell"},{"key":"B43","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1016\/j.ebiom.2019.10.058","article-title":"Identification of an immunotherapy-responsive molecular subtype of bladder cancer","volume":"50","author":"Song","year":"2019","journal-title":"EBioMedicine"},{"key":"B44","first-page":"31","article-title":"Superficial bladder cancer: an update on etiology, molecular development, classification, and natural history","volume":"10","author":"Pasin","year":"2008","journal-title":"Rev Urol"},{"key":"B45","doi-asserted-by":"publisher","first-page":"1692","DOI":"10.1016\/j.juro.2013.05.040","article-title":"The impact of histological reclassification during pathology re-review--evidence of a will rogers effect in bladder cancer?","volume":"190","author":"Linder","year":"2013","journal-title":"J Urol"},{"key":"B46","article-title":"Urinary and male genital tumours","volume-title":"WHO classification of tumours series","author":"Board","year":"2022"},{"key":"B47","doi-asserted-by":"publisher","first-page":"169","DOI":"10.3390\/cancers17020169","article-title":"Squamous cell bladder cancer: a rare histological variant with a demand for modern cancer therapeutics","volume":"17","author":"Bell","year":"2025","journal-title":"Journal"},{"key":"B48","doi-asserted-by":"publisher","first-page":"6565","DOI":"10.21037\/tcr-20-2169","article-title":"Variant histology in bladder cancer: diagnostic and clinical implications","volume":"9","author":"Black","year":"2020","journal-title":"Transl Cancer Res"},{"key":"B49","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1016\/j.eururo.2020.01.003","article-title":"Comprehensive assessment of immuno-oncology biomarkers in adenocarcinoma, urothelial carcinoma, and squamous-cell carcinoma of the bladder","volume":"77","author":"Necchi","year":"2020","journal-title":"Eur Urol"},{"key":"B50","doi-asserted-by":"publisher","first-page":"e394","DOI":"10.1016\/j.clgc.2023.05.007","article-title":"Impact of squamous histology on clinical outcomes and molecular profiling in metastatic urothelial carcinoma patients treated with immune checkpoint inhibitors or enfortumab vedotin","volume":"21","author":"Jindal","year":"2023","journal-title":"Clin Genitourinary Cancer"},{"key":"B51","doi-asserted-by":"publisher","first-page":"102356","DOI":"10.1016\/j.clgc.2025.102356","article-title":"Response and survival with immune checkpoint inhibitor in patients with advanced urothelial carcinoma and histology subtypes","volume":"23","author":"Bakaloudi","year":"2025","journal-title":"Clin Genitourin Cancer"},{"key":"B52","doi-asserted-by":"publisher","first-page":"1214","DOI":"10.1038\/s41416-020-01244-2","article-title":"Natural history, response to systemic therapy, and genomic landscape of plasmacytoid urothelial carcinoma","volume":"124","author":"Teo","year":"2021","journal-title":"Br J Cancer"},{"key":"B53","doi-asserted-by":"publisher","first-page":"101824","DOI":"10.1016\/j.xcrm.2024.101824","article-title":"PD-1 blockade plus cisplatin-based chemotherapy in patients with small cell\/neuroendocrine bladder and prostate cancers","volume":"5","author":"Gu","year":"2024","journal-title":"Cell Rep Med"},{"key":"B54","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1186\/s12894-022-01130-4","article-title":"Long-term complete response in small cell bladder carcinoma treated with carboplatin, etoposide, and atezolizumab","volume":"22","author":"Kamitani","year":"2022","journal-title":"BMC Urol"},{"key":"B55","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1002\/iju5.12208","article-title":"Successful treatment of recurrent small cell carcinoma of urinary bladder with pembrolizumab","volume":"3","author":"Hatayama","year":"2020","journal-title":"IJU Case Rep"},{"key":"B56","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1016\/j.ajpath.2019.09.007","article-title":"RNA expression profiling of lymphoepithelioma-like carcinoma of the bladder","volume":"98","author":"Manocha","year":"2018","journal-title":"Lab Invest"},{"key":"B57","doi-asserted-by":"publisher","first-page":"100588","DOI":"10.1016\/j.modpat.2024.100588","article-title":"Histopathologic, molecular, and clinical profiling of lymphoepithelioma-like carcinoma of the bladder","volume":"37","author":"Koll","year":"2024","journal-title":"Mod Pathol"},{"key":"B58","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.ejca.2022.02.022","article-title":"C-reactive protein flare predicts response to anti-PD-(L)1 immune checkpoint blockade in metastatic urothelial carcinoma","volume":"167","author":"Klumper","year":"2022","journal-title":"Eur J Cancer"},{"key":"B59","doi-asserted-by":"publisher","first-page":"602 e1","DOI":"10.1016\/j.urolonc.2020.02.005","article-title":"The pretreatment neutrophil-to-lymphocyte ratio is a novel biomarker for predicting clinical responses to pembrolizumab in platinum-resistant metastatic urothelial carcinoma patients","volume":"38","author":"Ogihara","year":"2020","journal-title":"Urol Oncol"},{"key":"B60","doi-asserted-by":"publisher","first-page":"1554048","DOI":"10.3389\/fimmu.2025.1554048","article-title":"Prognostic and predictive value of pre-treatment blood-based inflammatory biomarkers in patients with urothelial carcinoma treated with immune checkpoint inhibitors: a systematic review and meta-analysis","volume":"16","author":"Sz\u00e9les","year":"2025","journal-title":"Front Immunol"},{"key":"B61","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1002\/bco2.125","article-title":"FGFR2\/3 genomic alterations and response to enfortumab vedotin in metastatic urothelial carcinoma","volume":"3","author":"Adib","year":"2022","journal-title":"BJUI Compass"},{"key":"B62","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1007\/s00262-020-02709-2","article-title":"Early C-reactive protein kinetics predict survival of patients with advanced urothelial cancer treated with pembrolizumab","volume":"70","author":"Kijima","year":"2021","journal-title":"Cancer Immunol Immunother"},{"key":"B63","doi-asserted-by":"publisher","first-page":"3563","DOI":"10.21873\/invivo.12659","article-title":"Impact of C-reactive protein flare response in patients with advanced urothelial carcinoma who received pembrolizumab","volume":"35","author":"Tomisaki","year":"2021","journal-title":"Vivo"},{"key":"B64","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.21873\/anticanres.15576","article-title":"Platelet-to-Lymphocyte ratio predicts the efficacy of pembrolizumab in patients with urothelial carcinoma","volume":"42","author":"Kurashina","year":"2022","journal-title":"Anticancer Res"},{"key":"B65","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1007\/s00345-025-05452-4","article-title":"Prognostic scores for predicting overall survival in patients with metastatic renal and urothelial cancer undergoing immunotherapy - which one to use?","volume":"43","author":"Walach","year":"2025","journal-title":"World J Urol"},{"key":"B66","doi-asserted-by":"publisher","first-page":"Fso878","DOI":"10.2144\/fsoa-2023-0049","article-title":"Prognostic role of systemic inflammation indexes in metastatic urothelial carcinoma treated with immunotherapy","volume":"9","author":"Dionese","year":"2023","journal-title":"Future Sci OA"},{"key":"B67","doi-asserted-by":"publisher","first-page":"1850","DOI":"10.1200\/jco.2009.25.4599","article-title":"Prognostic factors in patients with advanced transitional cell carcinoma of the urothelial tract experiencing treatment failure with platinum-containing regimens","volume":"28","author":"Bellmunt","year":"2010","journal-title":"J Clin Oncol"},{"key":"B68","doi-asserted-by":"publisher","first-page":"17378","DOI":"10.1038\/s41598-023-44103-9","article-title":"Efficacy of immune checkpoint inhibitor therapy for advanced urothelial carcinoma in real-life clinical practice: results of a multicentric, retrospective study","volume":"13","author":"Varadi","year":"2023","journal-title":"Sci Rep"},{"key":"B69","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1016\/j.clgc.2021.11.010","article-title":"Enhanced bellmunt risk score for survival prediction in urothelial carcinoma treated with immunotherapy","volume":"20","author":"Abuhelwa","year":"2022","journal-title":"Clin Genitourin Cancer"},{"key":"B70","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1007\/978-1-4939-9773-2_13","article-title":"Development of gene expression-based biomarkers on the nCounter((R)) platform for immuno-oncology applications","volume":"2055","author":"Warren","year":"2020","journal-title":"Methods Mol Biol"},{"key":"B71","doi-asserted-by":"publisher","first-page":"2930","DOI":"10.1172\/JCI91190","article-title":"IFN-gamma-related mRNA profile predicts clinical response to PD-1 blockade","volume":"127","author":"Ayers","year":"2017","journal-title":"J Clin Invest"},{"key":"B72","doi-asserted-by":"publisher","first-page":"3503","DOI":"10.1038\/s41467-018-05992-x","article-title":"EMT- and stroma-related gene expression and resistance to PD-1 blockade in urothelial cancer","volume":"9","author":"Wang","year":"2018","journal-title":"Nat Commun"},{"key":"B73","doi-asserted-by":"publisher","first-page":"1251","DOI":"10.1038\/s41416-021-01488-6","article-title":"Fibroblast growth factor receptor 3 alterations and response to immune checkpoint inhibition in metastatic urothelial cancer: a real world experience","volume":"125","author":"Rose","year":"2021","journal-title":"Br J Cancer"},{"key":"B74","doi-asserted-by":"publisher","first-page":"2050","DOI":"10.1158\/1078-0432.CCR-21-3089","article-title":"Putative biomarkers of clinical benefit with pembrolizumab in advanced urothelial cancer: results from the KEYNOTE-045 and KEYNOTE-052 landmark trials","volume":"28","author":"Bellmunt","year":"2022","journal-title":"Clin Cancer Res"},{"key":"B75","doi-asserted-by":"publisher","first-page":"646982","DOI":"10.3389\/fcell.2021.646982","article-title":"Identification of an immune-related risk signature correlates with immunophenotype and predicts Anti-PD-L1 efficacy of urothelial cancer","volume":"9","author":"Li","year":"2021","journal-title":"Front Cell Dev Biol"},{"key":"B76","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1016\/j.ccell.2018.03.015","article-title":"The influence of the gut microbiome on cancer, immunity, and cancer immunotherapy","volume":"33","author":"Gopalakrishnan","year":"2018","journal-title":"Cancer Cell"},{"key":"B77","doi-asserted-by":"publisher","first-page":"1268","DOI":"10.1126\/science.1223490","article-title":"Interactions between the microbiota and the immune system","volume":"336","author":"Hooper","year":"2012","journal-title":"Science"},{"key":"B78","doi-asserted-by":"publisher","first-page":"847350","DOI":"10.3389\/fonc.2022.847350","article-title":"Gut microbiota: a promising milestone in enhancing the efficacy of PD1\/PD-L1 blockade therapy","volume":"12","author":"Zhou","year":"2022","journal-title":"Front Oncol"},{"key":"B79","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.1126\/science.aac4255","article-title":"Commensal bifidobacterium promotes antitumor immunity and facilitates anti-PD-L1 efficacy","volume":"350","author":"Sivan","year":"2015","journal-title":"Science"},{"key":"B80","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1126\/science.aad1329","article-title":"Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota","volume":"350","author":"V\u00e9tizou","year":"2015","journal-title":"Science"},{"key":"B81","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1016\/j.eururo.2020.06.061","article-title":"Concomitant antibiotic use and survival in urothelial carcinoma treated with atezolizumab","volume":"78","author":"Hopkins","year":"2020","journal-title":"Eur Urol"},{"key":"B82","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1016\/j.eururo.2021.05.018","article-title":"Is there a detrimental effect of antibiotic therapy in patients with muscle-invasive bladder cancer treated with neoadjuvant pembrolizumab?","volume":"80","author":"Pederzoli","year":"2021","journal-title":"Eur Urol"},{"key":"B83","doi-asserted-by":"publisher","first-page":"160 e11","DOI":"10.1016\/j.urolonc.2023.11.017","article-title":"Antibiotic use reduces the efficacy of immune checkpoint inhibitors in patients with urothelial carcinoma: a systematic review and meta-analysis","volume":"42","author":"Febriyanto","year":"2024","journal-title":"Urol Oncol"},{"key":"B84","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1007\/s00432-024-05728-z","article-title":"Impact of concurrent medications on clinical outcomes of cancer patients treated with immune checkpoint inhibitors: analysis of health insurance review and assessment data","volume":"150","author":"Hong","year":"2024","journal-title":"J Cancer Res Clin Oncol"},{"key":"B85","doi-asserted-by":"publisher","first-page":"842","DOI":"10.3390\/jpm12050842","article-title":"The impact of concomitant proton pump inhibitors on immunotherapy efficacy among patients with urothelial carcinoma: a meta-analysis","volume":"12","author":"Rizzo","year":"2022","journal-title":"J Pers Med"},{"key":"B86","doi-asserted-by":"publisher","first-page":"5487","DOI":"10.1158\/1078-0432.CCR-20-1876","article-title":"Concomitant proton pump inhibitor use and survival in urothelial carcinoma treated with atezolizumab","volume":"26","author":"Hopkins","year":"2020","journal-title":"Clin Cancer Res"},{"key":"B87","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1016\/j.eururo.2023.12.014","article-title":"Stool microbiome signature associated with response to neoadjuvant pembrolizumab in patients with muscle-invasive bladder cancer","volume":"85","author":"Pederzoli","year":"2024","journal-title":"Eur Urol"},{"key":"B88","doi-asserted-by":"publisher","first-page":"e0324814","DOI":"10.1371\/journal.pone.0324814","article-title":"Exploration of predictive factors based on oral and intestinal bacterial flora for treating patients with urothelial carcinoma","volume":"20","author":"Matsumoto","year":"2025","journal-title":"PLoS One"},{"key":"B89","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1186\/s12866-024-03372-8","article-title":"Gut microbiota Parabacteroides distasonis enchances the efficacy of immunotherapy for bladder cancer by activating anti-tumor immune responses","volume":"24","author":"Wang","year":"2024","journal-title":"BMC Microbiol"},{"key":"B90","doi-asserted-by":"publisher","first-page":"964","DOI":"10.1186\/s12967-024-05762-y","article-title":"Blautia coccoides and its metabolic products enhance the efficacy of bladder cancer immunotherapy by promoting CD8(+) T cell infiltration","volume":"22","author":"Wang","year":"2024","journal-title":"J Transl Med"},{"key":"B91","doi-asserted-by":"publisher","first-page":"3373","DOI":"10.1016\/j.cell.2024.05.029","article-title":"Custom scoring based on ecological topology of gut microbiota associated with cancer immunotherapy outcome","volume":"187","author":"Derosa","year":"2024","journal-title":"Cell"},{"key":"B92","doi-asserted-by":"publisher","first-page":"e100041","DOI":"10.1200\/EDBK_100041","article-title":"Clinical applications of the gut microbiome in genitourinary cancers","volume":"44","author":"Nguyen","year":"2024","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"B93","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1038\/s41591-022-01694-6","article-title":"Nivolumab plus ipilimumab with or without live bacterial supplementation in metastatic renal cell carcinoma: a randomized phase 1 trial","volume":"28","author":"Dizman","year":"2022","journal-title":"Nat Med"},{"key":"B94","doi-asserted-by":"publisher","first-page":"2576","DOI":"10.1038\/s41591-024-03086-4","article-title":"Cabozantinib and nivolumab with or without live bacterial supplementation in metastatic renal cell carcinoma: a randomized phase 1 trial","volume":"30","author":"Ebrahimi","year":"2024","journal-title":"Nat Med"},{"key":"B95","doi-asserted-by":"publisher","first-page":"2121","DOI":"10.1038\/s41591-023-02453-x","article-title":"Fecal microbiota transplantation plus anti-PD-1 immunotherapy in advanced melanoma: a phase I trial","volume":"29","author":"Routy","year":"2023","journal-title":"Nat Med"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-025-04189-2","article-title":"Fecal microbiota transplantation plus pembrolizumab and axitinib in metastatic renal cell carcinoma: the randomized phase 2 TACITO trial. 2026 Jan 28","author":"Porcari","year":"2026","journal-title":"Nat Med"},{"key":"B97","doi-asserted-by":"publisher","first-page":"11042","DOI":"10.1038\/s41598-020-67443-2","article-title":"Bladder cancer-related microbiota: examining differences in urine and tissue samples","volume":"10","author":"Mansour","year":"2020","journal-title":"Sci Rep"},{"key":"B98","doi-asserted-by":"publisher","first-page":"1242","DOI":"10.1016\/j.cmi.2022.08.010","article-title":"The urobiome in men and women: a clinical review","volume":"29","author":"Roth","year":"2023","journal-title":"Clin Microbiol Infect"},{"key":"B99","doi-asserted-by":"publisher","first-page":"110978","DOI":"10.1016\/j.urolonc.2025.12.014","article-title":"Does the urinary microbiome reflect the bladder-cancer-associated microbiome? Characterizing the microbiome in urine and cancer tissue in bladder cancer","volume":"44","author":"Hussein","year":"2026","journal-title":"Urol Oncol"},{"key":"B100","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1016\/j.euo.2020.04.002","article-title":"Sex-specific alterations in the urinary and tissue microbiome in therapy-naive urothelial bladder cancer patients","volume":"3","author":"Pederzoli","year":"2020","journal-title":"Eur Urol Oncol"},{"key":"B101","doi-asserted-by":"publisher","first-page":"1699308","DOI":"10.3389\/fmicb.2025.1699308","article-title":"Deciphering the urinary microbiome and urological cancers: from correlation to mechanisms and treatment","volume":"16","author":"Zheng","year":"2025","journal-title":"Front Microbiol"},{"key":"B102","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/s12866-021-02407-8","article-title":"Urogenital microbiota:potentially important determinant of PD-L1 expression in Male patients with non-muscle invasive bladder cancer","volume":"22","author":"Chen","year":"2022","journal-title":"BMC Microbiol"},{"key":"B103","doi-asserted-by":"publisher","first-page":"394","DOI":"10.3390\/cancers16020394","article-title":"Urinary microbiome dysbiosis and immune dysregulations as potential diagnostic indicators of bladder cancer","volume":"16","author":"Uzelac","year":"2024","journal-title":"Cancers (Basel)"},{"key":"B104","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1186\/s12967-024-05446-7","article-title":"Urinary microbiome dysbiosis is associated with an inflammatory environment and perturbed fatty acids metabolism in the pathogenesis of bladder cancer","volume":"22","author":"Wu","year":"2024","journal-title":"J Transl Med"},{"key":"B105","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1007\/s00262-024-03916-x","article-title":"Tumor-colonizing lachnoclostridium-mediated chemokine expression enhances the immune infiltration of bladder urothelial carcinoma","volume":"74","author":"Chen","year":"2025","journal-title":"Cancer Immunol Immunother"},{"key":"B106","doi-asserted-by":"publisher","first-page":"2280","DOI":"10.1158\/2159-8290.CD-22-0201","article-title":"Escherichia coli-specific CXCL13-Producing TFH are associated with clinical efficacy of neoadjuvant PD-1 blockade against muscle-invasive bladder cancer","volume":"12","author":"Goubet","year":"2022","journal-title":"Cancer Discov"}],"container-title":["Pathology &amp; Oncology Research"],"original-title":[],"link":[{"URL":"https:\/\/www.por-journal.com\/articles\/10.3389\/pore.2026.1612333\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,2]],"date-time":"2026-03-02T06:10:21Z","timestamp":1772431821000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.por-journal.com\/articles\/10.3389\/pore.2026.1612333\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,2]]},"references-count":106,"alternative-id":["10.3389\/pore.2026.1612333"],"URL":"https:\/\/doi.org\/10.3389\/pore.2026.1612333","relation":{},"ISSN":["1532-2807"],"issn-type":[{"value":"1532-2807","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,2]]},"article-number":"1612333"}}